DNLI - Company ID 0001714899
The table below shows Denali Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $330.53M | $108.46M | $48.66M | $335.66M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $418.78M | $396.44M | $423.88M | $358.73M | $265.35M | $212.62M |
| SG&A |
Denali Therapeutics Inc. reported annual revenue of $0.00 for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $136.56M |
| $105.44M |
| $103.35M |
| $90.47M |
| $79.06M |
| $60.33M |
| Operating income | -$555.34M | -$487.34M | -$196.70M | -$340.74M | -$295.75M | $62.72M |
| Income tax | $102.00K | $68.00K | $30.00K | $21.00K | -$575.00K | $823.00K |
| Net income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M | $71.14M |
| EPS (diluted) | -$2.97 | -$2.57 | -$1.06 | -$2.60 | -$2.39 | $0.63 |